Calcium AKG

Calcium Alpha-Ketoglutarate (Ca-AKG) is an intermediate in the Krebs cycle — a metabolic hub your cells use to generate energy — and the reason it has attracted longevity researchers is that circulating AKG levels decline by roughly 10-fold between ages 40 and 80. In animal models, Ca-AKG supplementation has extended median lifespan by 10–16% in mice, reduced frailty markers, and supported bone density. Human evidence is early but notable: a 2021 observational study of 42 individuals taking Ca-AKG for 4–10 months found an average 8-year reduction in DNA methylation age — a biological age marker — though the study lacked a control group. The ABLE trial, a double-blind RCT of 120 middle-aged participants, is actively investigating Ca-AKG versus placebo on methylation age and metabolic parameters, with results expected to sharpen (or challenge) the current picture. Proposed mechanisms include activation of AMPK longevity pathways, inhibition of mTOR, free radical scavenging, and autophagy support. Adults in midlife or beyond concerned with healthspan and metabolic aging are the target audience; safety data from human studies to date has been favorable with no notable adverse effects. Genuinely interesting science in its early innings — probably worth watching, possibly worth trying.

Also known as: Alpha-Ketoglutarate, AKG